Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

US: CAFC confirms that patents must meet both the written description and enablement requirements of section 112: Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co. (En Banc Decision) (Patently-O) (Patent Docs) (Holman’s Biotech IP Blog) (Inventive Step)

Angiomax (Bivalirudin): PTO once again denies PTE for Angiomax patent… but not before issuing an interim extension; The Medicines Company is outraged (FDA Law Blog) (IP Factor)

Biodiversity negotiators seek to finalise draft access, benefit-sharing regime (IP Watch)

Efficacy of TRIPS public health amendment raises concern at the WTO (IP Osgoode)

50 best blogs for biotech (Patent Baristas)

EU: Paediatric extensions: another article – EIPR article ‘The Legal Scope and Content of the Right to SPC Extension under the Paediatric Regulation’ (SPC Blog)

EU: Record of IP Institute’s meeting on Paediatric Extensions now available (SPC blog)

Israel: Teva buys Germany’s Ratiopharm (IP Factor) (Genericsweb)

Kenya/US: Another plant based patent germinates – US patent on medicinal composition derived from Kenyan plant (Afro-IP)

UK: IPO finds cosmetic treatment patentable: BL O/058/10 (IPKat)

US: CAFC confirms that patents must meet both the written description and enablement requirements of section 112: Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co. (En Banc Decision) (Patently-O) (Patent Docs) (Holman’s Biotech IP Blog) (Inventive Step)

US: CAFC transfers ‘hot potato’ diagnostic method case: Laboratory Corp. of America Holdings v. Metabolite Laboratories, Inc. (Patent Docs)

US: House passes Health Care Reform Bill – Biosimilar regulatory pathway makes cut, pay-for-delay ban does not (Patent Docs)

US: False marking claims in the U.S: A different kind of patent litigation (Genericsweb)

US: FDA relies on drug listing information in the latest round of marketed unapproved drug warning letters (FDA Law Blog)

Adcirca (Tadalafil) – US: Patent infringement complaint filed following a Para IV certification: Eli Lilly and Company, et al. v. Synthon Pharmaceuticals, Inc. (Patent Docs)

Angiomax (Bivalirudin): PTO once again denies PTE for Angiomax patent… but not before issuing an interim extension; The Medicines Company is outraged (FDA Law Blog) (IP Factor)

Aricept (Donepezil) – Spain: Commercial Court No 5 Barcelona confirms previous decision granting interim injunction inaudita parte against Mylan temporarily banning commercialisation of generic Donepezil: Eisai & Pfizer v. Mylan (EPLAW)

Colmetec (Olmesartan medoxomil, Hydrochlorothiazide) – France: Cour d’Appel of Paris dismisses appeal of Daiichi Sankyo lodged against decision of French Patent Office rejecting its French SPC: Daiichi Sankyo Company Limited v. INPI (EPLAW)

Lyrica (Pregabalin) – US: Patent infringement complaint filed following a Para IV certification: Pfizer Inc. et al. v. Alphapharm Pty Ltd. et al. (Patent Docs) (Patent Quality Review Blog)

Nuvigil (Armodafinil) – US: Patent infringement complaint filed following a Para IV certification: Cephalon, Inc. et al. v. Lupin Ltd. et al. (Patent Docs)

Reyataz (Atazanavir): US: Patent infringement complaint filed following a Paragraph IV certification: Bristol-Myers Squibb Co. et al. v. Teva Pharamceuticals USA, Inc. (Patent Docs) (IP Factor)

Telfast (Fexofenadine) – Netherlands: Court of Appeal holds Aventis not entitled to preliminary injunction because serious chance of nullification of patent in case on merits: Aventis v Apothecon and Ratiopharm (EPLAW)

Temodar (Temozolomide) – US: Teva comes to agreement with Barr and Schering regarding Temodar (IP Factor)

Trilipix (Fenofibrate) – US: Patent infringement complaint filed following a Paragraph IV certification: Abbott Laboratories et al. v. Impax Laboratories, Inc. (Patent Docs)